

FILED ELECTRONICALLY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

In re Application of: Steven Bernstein et al.

Serial No.: 10/534,612

Group No.: 1618

Filed: 11/25/2003

Examiner: Zohreh Fay

For: PHARMACEUTICAL FORMULATIONS OF CELECOXIB

Attorney Docket Number: TPIP017C/WO US

---

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF FILING APPLICATION OR BEFORE MAILING OF A  
FIRST OFFICE ACTION ON THE MERITS (37 CFR 1.97(b))**

Dear Sir:

Applicant submits herewith patents, publications or other information of which, in good-faith judgment of the Applicant, may be relevant to the subject matter claimed in the above-identified application and in respect of which, there may be a duty to disclose. Applicant submits these documents in compliance with the duty of disclosure as defined in 37 CFR §1.56, §1.97, and §1.98. The Examiner is requested to make these citations of official record in the present application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

The Information Disclosure Statement transmitted herewith is being filed *after* three months of the filing date of this national application but *before* the mailing date of the first Office action on the merits. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 100750.

Only copies of any foreign patent documents and non-patent literature listed in Form PTO/SB/08a are enclosed. Should the Examiner require a copy of a patent reference listed, the Examiner is invited to contact the undersigned.

The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO/SB/08a be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

Respectfully submitted,

Dated: November 17, 2006  
Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933  
Telephone: (781) 674-7816  
Facsimile: (732) 524-2808

/Paul Burgess/  
Paul Burgess, Attorney for Applicants  
Reg. No. 53,852  
Customer No. 27777